Top entities: Unicycive Therapeutics, United States — Food and Drug Administration.

What category does this event fall under?

Business — classified as securities lawsuit.

What is the sentiment of coverage?

Aggregate sentiment score: -40 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Is this event still developing?

This event is archived — the story has concluded and this page is a final snapshot.

Business securities lawsuit

Unicycive Therapeutics faces securities lawsuit

Q: When did this event occur?

First reported Aug 21, 2025; last updated Sep 25, 2025.

Q: What is the market impact?

General. The market is impacted by the potential financial liabilities and reputational damage to Unicycive Therapeutics due to the securities class action lawsuit.

Analysis based on 9 articles · First reported Aug 21, 2025 · Last updated Sep 25, 2025

Sentiment

-40

Attention

Articles

Market Impact

General

Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

Market Impact

The market is impacted by the potential financial liabilities and reputational damage to Unicycive Therapeutics due to the securities class action lawsuit. Investors who purchased shares during the class period may seek recovery, potentially affecting Unicycive Therapeutics' stock price.

pharmaceuticals legal services

Event Summary

The Gross Law Firm has issued multiple notices to shareholders of Unicycive Therapeutics, informing them of a class action lawsuit. The lawsuit alleges that Unicycive Therapeutics made materially false and/or misleading statements between March 29, 2024, and June 27, 2025. Specifically, the complaint claims that Unicycive Therapeutics overstated its ability to meet the United States — Food and Drug Administration's manufacturing compliance requirements and the regulatory prospects of its oxylanthanum carbonate new drug application. Shareholders are encouraged to contact The Gross Law Firm to discuss lead plaintiff appointment, with a deadline of October 14, 2025.

Entities Involved

stock

Unicycive Therapeutics

Unicycive Therapeutics is being sued for allegedly issuing materially false and/or misleading statements regarding its readiness to satisfy FDA manufacturing compliance requirements and the regulatory prospects of its oxylanthanum carbonate new drug application.

Importance 100.0 Sentiment -70.0

govactor

United States — Food and Drug Administration

Importance 0.0 Sentiment 0.0

Relationships

Unicycive Therapeutics related ↔ United States — Food and Drug Administration

ERGEN INTELLIGENCE

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard